Abstract: Provided herein are agents, such as antibodies, antibody-drug conjugates, or chimeric antigen receptors, that target EphA10. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an EphA10-targeting agent. The patient may be selected for treatment if the cancer expresses an increased level of EphA10.

Abstract: The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury.

Abstract: The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury.

Abstract: The present invention relates to a method for fabricating an electrochemical sensor which can highly sensibly detect a hydrogen gas by adapting Me4NOH.5H2O as a proton conductor. In the present invention, Me4NOH.5H2O with a high ion conductivity and a reliable thermal stability is adapted as a proton conductor, and a carbon electrode on which a platinum dispersed in an organic solvent is loaded, is used as an anode. It is possible to fabricate a new type electrochemical sensor which adapts an ionic clathrate hydrate capable of reliably detecting hydrogen gas.